Status:

COMPLETED

Role of Minocycline in First Episode Psychosis

Lead Sponsor:

Stanley Medical Research Institute

Collaborating Sponsors:

Institute of Psychiatry, Rawalpindi Medical College, Pakistan

Pakistan Institute of Living and Learning

Conditions:

First Episode Psychosis

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this study is to determine whether the addition of minocycline or placebo to treatment as usual (TAU): 1. prevents the accumulation of negative symptoms and intellectual decline follow...

Detailed Description

Background: There is increasing clinical, neuropsychological and imaging evidence that schizophrenia involves a progressive process at the time of the first episode and later in life. However, it is ...

Eligibility Criteria

Inclusion

  • Aged 18 to 65 years
  • Diagnostic and Statistical Manual-IV (DSM-IV) diagnosed first episode psychosis, schizophrenia, schizoaffective disorder, psychosis not otherwise specified or schizophreniform disorder
  • First episode (within first 5 years of diagnosis)
  • Competent and willing to give informed consent
  • Medication remained stable 4 weeks prior to baseline
  • Able to take oral medication and likely to complete the required evaluations
  • Female participants of child bearing capability must be willing to use adequate contraceptives for the duration of the study, and, willing to have a pregnancy test pre-treatment and at ten weekly intervals while on study medication

Exclusion

  • Relevant medical illness \[renal, hepatic, cardiac, serious dermatological disorders such as exfoliative dermatitis, systemic lupus erythematosus (SLE)\] in the opinion of the investigators (see section 6.2a)
  • Prior history of intolerance to any of the tetracyclines
  • Concomitant penicillin therapy
  • Concomitant anticoagulant therapy
  • Presence of a seizure disorder, not including clozapine-induced seizures
  • Presently taking valproic acid
  • Any change of psychotropic medications within the previous six weeks
  • Diagnosis of substance abuse (except nicotine or caffeine) or dependence within the last three months according to DSM-IV criteria
  • Pregnant or breast-feeding

Key Trial Info

Start Date :

May 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2008

Estimated Enrollment :

52 Patients enrolled

Trial Details

Trial ID

NCT00916461

Start Date

May 1 2006

End Date

March 1 2008

Last Update

June 15 2009

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Department of Neurology, Psychiatry and Psychological Medicine, University of San Paulo

São Paulo, Brazil

2

Civil Hospital Karachi

Karachi, Pakistan

3

Karwan e Hayat

Karachi, Pakistan

4

Institute of Psychiatry, Rawalpindi medical College

Rawalpindi, Pakistan